Shares of Pharvaris N.V. (PHVS) surged 5.94% on Friday, marking a strong finish to the trading week for the biopharmaceutical company. The stock's intraday surge came amid bullish analyst sentiment.
Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris and set a price target of $34.00, reflecting a significant upside potential from current levels. The analyst's positive outlook appears to be fueling investor optimism and driving the stock higher.
Pharvaris is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare diseases. The company's promising pipeline and growth prospects have caught the attention of Wall Street analysts, contributing to the stock's recent momentum.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.